Recent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK inhibitors unless there is no other alternative.
LIVERPOOL, ENGLAND — Four in five people with rheumatoid arthritis fall into"at risk" categories for the initiation of Janus kinase inhibitors set by the European Medicines Agency , according to data from the long-running British Society for Rheumatology Biologics Register in RA .to implement measures to reduce the risk for serious side effects with JAK inhibitors in the treatment of chronic inflammatory diseases.
Moreover, the bigger question is what to do with all the people who are already established on a JAK inhibitor, Emery said. Should patients now switch off their medication? Doing so may well leave them with a period of inflammation that may be more harmful than continuing the JAK inhibitor, he suggested.
"In my opinion, the really key thing is to be able to communicate the issues with integrity, in a manner that the patient understands, to make sure that the risk is acceptable to them," Taylor said. McInnes, honorary consultant rheumatologist and vice principal and head of the College of Medical Veterinary & Life Sciences at the University of Glasgow in Glasgow, Scotland, pointed out that the EMA warnings assume that all JAK inhibitors are the same, but is that really the case? This is complex biochemistry, and could newer JAK inhibitors have an improved safety profile?"There is no free ride in the immune system, and we should bear that in mind," McInnes said.
RA - Rheumatoid Arthritis Rheumatoid Arthritis (RA) Disease-Modifying Antirheumatic Drugs Dmards DMARD Jak/Stat Jak-Stat Signaling Pathway Jak-Stat Cytokine Receptors Thromboembolism Arthritis Joint Inflammation Biologic Therapy Biologics Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Grant CV Risk Cardiovascular Risk CV Risk Factors
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bone Infections Increase After S aureus Bacteremia in Patients With Rheumatoid ArthritisThe use of orthopedic implants or tumor necrosis factor inhibitors doubled the risk for bone infections in patients with RA who had contracted S aureus bacteremia.
Read more »
Higher Risk of Osteoarticular Infections in Patients with Rheumatoid ArthritisPatients with rheumatoid arthritis (RA) face nearly double the risk for osteoarticular infections compared with those without RA, with similar mortality risks in both groups.
Read more »
Patients in Remission Experience More Flares After Stopping Rheumatoid Arthritis MedicationA study found that patients with rheumatoid arthritis who tapered and stopped their medication experienced more disease flares compared to those who continued with a stable dose. Patients who took only conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and remained on a stable dose had a higher flare-free rate compared to those who tapered and discontinued the medication. Similar results were observed in patients who tapered tumor necrosis factor (TNF) inhibitor therapy.
Read more »
Why some people with rheumatoid arthritis have pain without inflammationResearchers have identified a suite of genes explaining the disconnect between diagnosis and symptom.
Read more »
High Infection Risk in Rheumatoid Arthritis–Associated Interstitial Lung DiseaseA prospective study found that 96% of patients with RA-ILD had at least one serious infection, which proved fatal in 65% of cases.
Read more »
Tennis pro Danielle Collins opens up about retiring amid battle with endometriosis, rheumatoid arthritisDanielle Collins is now the 15th-ranked player in the world.
Read more »